Evaluation of the Efficacy and Safety of Romosozumab (Evenity) for the Treatment of Osteoporotic Vertebral Compression Fracture in Postmenopausal Women: A Systematic Review and Meta-analysis of Randomized Controlled Trials (CDM-J).

Our meta-analysis revealed the evident advantages of romosozumab in the treatment of osteoporosis and low BMD in postmenopausal women and increased risks of hypersensitivity and injection site reactions. This article is protected by copyright. All rights reserved.